Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HURRICANE (LCH-LT04) – Tislelizumab + chemotherapy and local treatment in stage III-N3 NSCLC
ChiCTR2500104270Phase 2Not yet recruiting
- Sponsor
- Liaoning Province Cancer Hospital
- Start
- Jun 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in non-small cell lung cancer (NSCLC), sponsored by Liaoning Province Cancer Hospital. Primary endpoint: 1-year event-free survival rate (1y-EFS rate). Planned start Jun 2025; status: not yet recruiting.
02
Drugs
tislelizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2500104270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500104270.